WT1-specific immunological assessments in WT1-peptide-based cancer vaccine in combination with gemcitabine for patients with advanced pancreatic cancer
Project/Area Number |
21790665
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Single-year Grants |
Research Field |
Gastroenterology
|
Research Institution | Osaka University |
Principal Investigator |
NISHIDA Sumiyuki 大阪大学, 大学院・医学系研究科, 寄附講座助教 (00403189)
|
Project Period (FY) |
2009 – 2011
|
Project Status |
Completed (Fiscal Year 2011)
|
Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Keywords | 胆道学 / 膵臓学(膵臓癌) / 膵臓癌 / WT1 / 癌免疫療法 / 細胞傷害性リンパ球 / 細胞障害性リンパ球 |
Research Abstract |
A clinical study of WT1-peptide-based cancer vaccine(WT1 vaccine) in combination with gemcitabine was performed for the patients with advanced pancreatic cancer. I focused on the association between clinical efficiency and WT1-specific immunological monitoring, such as i) delayed-type hypersensitivity(DTH) to WT1 peptide and ii) WT1-specific cytotoxic lymphocytes in the peripheral blood(WT1-CTLs). An association between longer survival and DTH-positivity was statistically significant, and longer survivors had higher frequency of WT1-CTLs with memory phenotype.
|
Report
(4 results)
Research Products
(20 results)